IP Library Granted Patent US 9,944,951
Granted Patent B2
US 9,944,951 · App. 13/114,921 · Granted Apr 17, 2018

Chromosome 3p21.3 genes are tumor suppressors

Inventors: Lin Ji (Sugar Land, TX); John Dorrance Minna (Dallas, TX); Jack Roth (Houston, TX); Michael Lerman (Rockville, MD)
Assignees: Board of Regents, The University of Texas System; The United States of America as represented by the Secretary of the Department of Health and Human Services
C12N15/86A01K67/0271A01K67/0275A61K48/00C07K14/4703C12N15/8509C12Q1/6886A01K2217/05A01K2217/075A01K2217/20A01K2227/105A01K2267/0331C12N2710/10343C12N2830/006C12Q2600/118C12Q2600/136C12Q2600/154Y10S977/916
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,944,951
App. No.
13/114,921
Granted
Apr 17, 2018
Kind
B2
Abstract

Tumor suppressor genes play a major role in the pathogenesis of human lung cancer and other cancers. Cytogenetic and allelotyping studies of fresh tumor and tumor-derived cell lines showed that cytogenetic changes and allele loss on the short arm of chromosome 3 (3p) are most frequently involved in about 90% of small cell lung cancers and greater than 50% of non-small cell lung cancers. A group of recessive oncogenes, Fus1, 101F6, Gene 21 (NPRL2), Gene 26 (CACNA2D2), Luca 1 (HYAL1), Luca 2 (HYAL2), PL6, 123F2 (RaSSFI), SEM A3 and Beta* (BLU), as defined by homozygous deletions in lung cancers, have been located and isolated at 3p21.3.

Claims (6)

1. A method of altering the phenotype of a lung tumor cell comprising contacting said cell with an expression cassette comprising:

(a) an isolated polynucleotide encoding a human FUS1 polypeptide; and

(b) a heterologous promoter active in said tumor cell, under conditions permitting the uptake of said polynucleotide by said tumor cell.

2. The method of claim 1 , wherein the phenotype is selected from the group consisting of proliferation, migration, contact inhibition, soft agar growth, cell cycling, invasiveness, tumorigenesis, and metastatic potential.

3. The method of claim 1 , wherein said promoter is a cytomegalovirus (CMV) promoter.

4. The method of claim 1 , wherein said expression cassette is contained in a lipid preparation.

Assignments (1)
CONFIRMATORY LICENSE Recorded Jul 16, 2018
From: UNIVERSITY OF TX MD ANDERSON CAN CTR
To: NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT
Reel/Frame 046547/0439 →
Continuity (5)
Continuation 11932724 · Oct 31, 2007
Continuation 10445718 · May 27, 2003
Division 09902003 · Jul 10, 2001
Provisional Application 60217112 · Jul 10, 2000
Related Publication 20120076851A1 · Mar 29, 2012